Journal Title：Expert Opinion On Biological Therapy

Expert Opinion on Biological Therapy (1471-2598; 1744-7682) is a MEDLINE-indexed, international journal publishing peer-reviewed research across all aspects of biological therapy.

Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.

The audience consists of scientists and managers in the healthcare and biopharmaceutical industries and others closely involved in the development and application of biological therapies for the treatment of human disease.

The journal welcomes:

Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicine

Drug evaluations reviewing the clinical data on a particular biological agent

Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice

Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:

Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results;

Article Highlights – an executive summary of the author’s most critical points.

《生物治療專家意見》（1471-2598；1744-7682）是一本 MEDLINE 索引的國際期刊，發(fā)表涉及生物治療各個方面的同行評審研究。

每篇文章的結構都結合了作者自己對該主題對研究和臨床實踐的影響以及未來發(fā)展范圍的專家意見。

讀者包括醫(yī)療保健和生物制藥行業(yè)的科學家和管理人員，以及其他與開發(fā)和應用生物療法治療人類疾病密切相關的人。

該期刊歡迎：

涵蓋治療性抗體和疫苗、肽和蛋白質、基因療法和基因轉移技術、細胞療法和再生醫(yī)學的評論

審查特定生物制劑臨床數(shù)據(jù)的藥物評估

原創(chuàng)研究論文，報告與生物制劑和生物治療研究密切相關的臨床研究結果臨床實踐

每篇評論的全面報道都由獨特的專家精選格式補充，并包括以下部分：

專家意見——對文章中呈現(xiàn)的數(shù)據(jù)的個人看法，對未來可能重要的發(fā)展進行討論，以及隨著進一步研究產(chǎn)生更詳細的結果，可能變得令人興奮的研究途徑；

文章重點——作者最關鍵觀點的執(zhí)行摘要。

Expert Opinion On Biological Therapy創(chuàng)刊于2001年，由Taylor and Francis Ltd.出版商出版，收稿方向涵蓋生物工程與應用微生物 - 醫(yī)學全領域，此刊是中等級別的SCI期刊，所以過審相對來講不是特別難，但是該刊專業(yè)認可度不錯，仍然是一本值得選擇的SCI期刊 。平均審稿速度 一般,3-8周 ，影響因子指數(shù)3.6，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。